Direct costs of three models for the screening of latent tuberculosis infection

European Respiratory Journal

Volumn 28, Issue 1, 2006, Pages 45-50

  Wrighton Smith, P ^a   Zellweger, Jean Pierre ^b  

^a Oxford Immunotec   (United Kingdom)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Contact tracing; Interferon releaseassays; Latent tuberculosis infection; Screening; Tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; TUBERCULIN;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSPOT ASSAY; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; MODEL; MYCOBACTERIUM TUBERCULOSIS; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCREENING TEST; SWITZERLAND; THORAX RADIOGRAPHY; TUBERCULIN TEST;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; INTERFERON TYPE II; MASS SCREENING; MYCOBACTERIUM TUBERCULOSIS; PUBLIC HEALTH; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; SWITZERLAND; TUBERCULIN TEST; TUBERCULOSIS;

EID: 33748419211     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00005906     Document Type: Article

References (34)

1. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
2. Lalvani A, Pathan A, McShane H, et al. Rapid detection of mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001; 163: 824-828.
3. Barnes PF. Diagnosing latent tuberculosis infection: the 100-year upgrade. Am J Respir Crit Care Med 2001; 163: 807-808.
4. Lalvani A. Spotting latent infection: the path to better tuberculosis control. Thorax 2003; 58: 916-918.
5. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA micro-array. Science 1999; 284: 1520-1523.
6. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356: 1099-1104.
7. Lalvani A, Pathan A, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001; 357: 2017-2021.
8. Chapman A, Munkanta M, Wilkinson K, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16: 2285-2293.
9. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361: 1168-1173.
10. Richeldi L, Ewer K, Bergamini B, et al. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 2004; 170: 288-294.
11. Richeldi L, Ewer K, Losi M, et al. Early diagnosis of sub-clinical multidrug-resistant tuberculosis. Annals Internal Med 2004; 140: 709-713.
12. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan A, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004; 364: 2196-2203.
13. Zellweger J-P, Zellweger A, Ansermet S, de Senarclens B, Wrighton-Smith P. New T cell based test correlated better with tuberculosis exposure than tuberculin skin test. Int J Tuberc Lung Dis 2005; 9: 1242-1247.
14. Meier T, Eulenbruch H, Wrighton-Smith P, Enders G, Regnath T. Evaluation of a new commercial enzyme-linked immunospot assay (T-SPOT.TB) for the diagnosis of tuberculosis in routine clinical practice. Eur J Clin Microbiol Infect Dis 2005; 24: 529-536.
15. Shams H, Weis S, Klucar P, et al. Enzyme-linked immuno-spot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005; 172: 1161-1168.
16. Soysal A, Millington K, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005; 366: 1443-1451.
17. Dheda K, Lalvani A, Miller R, et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 2005; 19: 2038-2041.
18. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170: 59-64.
19. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170: 65-69.
20. Ligue pulmonaire suisse et Office fédéral de la santé publique. Manuel de la tuberculose. Berne, Ligue Pulmonaire Suisse, 2003; pp. 1-37.
21. National Institute for Clinical Excellence (NICE). Tuberculosis. National clinical guideline for diagnosis, management, prevention, and control. Wetherby, UK, National Institute for Clinical Excellence, 2006.
22. Dasgupta K, Schwartzman K, Marchand R, Tennenbaum T, Brassard P, Menzies D. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000; 162: 2079-2086.
23. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J 2005; 26: 465-473.
24. Salpeter S, Salpeter E. Screening and treatment of latent tuberculosis among healthcare workers at low, moderate and high risk for tuberculosis exposure: a cost-effectiveness analysis. Infect Control Hosp Epidemiol 2004; 25: 1056-1061.
25. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 161: 780-789.
26. Salpeter S, Sanders G, Salpeter E, Owens D. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age. A risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127: 1051-1061.
27. Rose D. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. Ann Intern Med 1998; 129: 779-786.
28. Schechter C, Rose D, Fahs M, Silver A. Tuberculin screening: cost-effectiveness analysis of various testing schedules. Am J Prev Med 1990; 6: 167-175.
29. Walker D. Economic analysis of tuberculosis diagnostic tests in disease control: how can it be modelled and what additional information is needed? Int J Tuberc Lung Dis 2001; 5: 1099-1108.
30. Huebner R, Schein M. The tuberculin skin test. Clin Infect Dis 1993; 17: 968-975.
31. Anastos K, Kalish LA, Palacio H, et al. Prevalence of and risk factors for tuberculin positivity and skin test anergy in HIV-1-infected and uninfected at-risk women. Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 1999; 21: 141-147.
32. Johnson JL, Nyole S, Okwera A, et al. Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration. Am J Respir Crit Care Med 1998; 158: 1790-1796.
33. Tissot F, Zanetti G, Francioli P, Zellweger JP, Zysset F. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005; 40: 211-217.
34. Collet E, Krahenbuhl JD, Gehri M, Bissery A, Zellweger JP. Risk factors for positive tuberculin skin tests among migrant and resident children in Lausanne, Switzerland. Swiss Med Wkly 2005; 135: 703-709.